1. Pink Sheet
  2. >>Pathways & Standards
  3. >>Approval Standards

US FDA’s Patient-Focused Drug Development Program Meetings Evolve With Technology Focus

 
• By Derrick Gingery

A recent externally-led PFDD meeting on kidney xenotransplantation, rather than a specific disease, allowed for more tailored patient comments on the procedure, which could impact development plans going forward.

evolution
The FDA's PFDD program is evolving to tackle new areas for patient input. • Source: Shutterstock

The next evolution of the US Food and Drug Administration’s Patient-Focused Drug Development Program could be meetings focused on specific technologies or treatment approaches.

Most PFDD meetings have focused on a specific disease or collection of diseases, as well as adverse events associated with a disease. A 9 November externally-led PFDD meeting focused on...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approval Standards

More from Pathways & Standards